Cancer Epidemiology Biomarkers and Prevention

American Association for Cancer Research (AACR)
American Association for Cancer Research (AACR)
ISSN: 10559965, 15387755

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
SCImago
Q1
WOS
Q1
Impact factor
3.7
SJR
1.688
CiteScore
6.5
Categories
Epidemiology
Medicine (miscellaneous)
Oncology
Areas
Medicine
Years of issue
1983, 1986, 1991-2025
journal names
Cancer Epidemiology Biomarkers and Prevention
CANCER EPIDEM BIOMAR
Publications
12 794
Citations
275 889
h-index
171
Top-3 citing journals
Top-3 organizations
National Cancer Institute
National Cancer Institute (1285 publications)
Harvard University
Harvard University (791 publications)
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center (713 publications)
Top-3 countries
USA (9161 publications)
United Kingdom (755 publications)
Canada (584 publications)

Most cited in 5 years

Found 
from chars
Publications found: 900
An update on emerging anti-amyloid-β monoclonal antibodies for treating Alzheimer’s disease: the role of apolipoprotein E
Lozupone M., Dibello V., Daniele A., Panza F.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging immune tolerance therapies for neuromyelitis optica spectrum disorder
Carnero Contentti E., Correale J.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging treatments for sarcoma: from 2024 onward
Gómez-Puerto D., Cicala C.M., Valverde C., Serrano C.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Emerging biological treatments for asthma
Pastore D., Lupia C., D’Amato M., Bruni A., Garofalo E., Longhini F., Gallelli L., Vatrella A., Pelaia G., Pelaia C.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Mitapivat: a step forward across different hemolytic diseases
Hodroj M.H., Klim J., Charbel N., Taher A.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
FcRn inhibitors in the context of myasthenia gravis
Menon D., Bhandari V.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Muscarinic M1 and M4 agents as treatments for schizophrenia: what do they do and who do they do it for?
Harvey P.D.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Systemic therapy for Child-Pugh B patients with hepatocellular carcinoma
Mok K., Chen O., Yau J., Chan L.L., Chan S.L.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Seltorexant for major depressive disorder
Valentino K., Teopiz K.M., Wong S., Zhang M.C., Le G.H., Choi H., Ballum H., Dri C., Cheung W., McIntyre R.S.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2025 citations by CoLab: 0
Exploring emerging JAK inhibitors in the treatment of aicardi-goutières syndrome
Politano D., Tonduti D., Battini R., Fazzi E., Orcesi S.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
Monoclonal antibodies in phase II and III trials for moderate to severe atopic dermatitis
Patel H.A., Tran L., Karagenova R., Feldman S.R.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
ONC201 (Dordaviprone): review of evidence to date in diffuse midline glioma, hope or hype?
Hansford J.R., Manoharan N., Bouche G., Ramaswamy V., Jabado N., Bouffet E.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
Promising PD-1 antagonists for liver cancer: an evaluation of phase II and III results
Stella L., Hollande C., Merabet Y.B., Fakhouri H., Leclerc V., Ponziani F.R., Bouattour M.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0
A comprehensive review of phase 2/3 trials in osteoarthritis: an expert opinion
Pan L., Nagib L., Ganguly S., Moorthy A., Tahir H.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 1
Current and emerging drug treatment strategies to tackle sickle cell anemia
Persaud Y., Leonard A., Rai P.
Q1
Taylor & Francis
Expert Opinion on Emerging Drugs 2024 citations by CoLab: 0

Top-100

Citing journals

1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
Show all (70 more)
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000

Citing publishers

10000
20000
30000
40000
50000
60000
Show all (70 more)
10000
20000
30000
40000
50000
60000

Publishing organizations

200
400
600
800
1000
1200
1400
Show all (70 more)
200
400
600
800
1000
1200
1400

Publishing organizations in 5 years

50
100
150
200
250
300
350
400
Show all (70 more)
50
100
150
200
250
300
350
400

Publishing countries

1000
2000
3000
4000
5000
6000
7000
8000
9000
10000
USA, 9161, 71.6%
United Kingdom, 755, 5.9%
Canada, 584, 4.56%
China, 469, 3.67%
Germany, 407, 3.18%
Australia, 400, 3.13%
Sweden, 397, 3.1%
France, 374, 2.92%
Italy, 328, 2.56%
Netherlands, 316, 2.47%
Denmark, 234, 1.83%
Spain, 218, 1.7%
Norway, 217, 1.7%
Republic of Korea, 207, 1.62%
Japan, 187, 1.46%
Finland, 164, 1.28%
Mexico, 144, 1.13%
Puerto Rico, 117, 0.91%
Nigeria, 97, 0.76%
Greece, 95, 0.74%
Poland, 76, 0.59%
Brazil, 68, 0.53%
New Zealand, 67, 0.52%
Israel, 65, 0.51%
Austria, 56, 0.44%
Belgium, 54, 0.42%
Colombia, 54, 0.42%
Turkey, 46, 0.36%
Czech Republic, 43, 0.34%
India, 42, 0.33%
Switzerland, 42, 0.33%
Singapore, 41, 0.32%
Ireland, 40, 0.31%
Saudi Arabia, 38, 0.3%
Malaysia, 31, 0.24%
Russia, 28, 0.22%
Portugal, 25, 0.2%
Iceland, 24, 0.19%
Hungary, 22, 0.17%
Kenya, 22, 0.17%
Egypt, 21, 0.16%
Ghana, 20, 0.16%
Tanzania, 19, 0.15%
Costa Rica, 18, 0.14%
Romania, 18, 0.14%
Argentina, 17, 0.13%
Guam, 17, 0.13%
Thailand, 17, 0.13%
Chile, 17, 0.13%
Georgia, 16, 0.13%
Ethiopia, 16, 0.13%
Slovakia, 15, 0.12%
South Africa, 15, 0.12%
Vietnam, 14, 0.11%
Iran, 12, 0.09%
Lebanon, 12, 0.09%
Jamaica, 12, 0.09%
Peru, 11, 0.09%
Bangladesh, 10, 0.08%
Uganda, 10, 0.08%
Bahamas, 9, 0.07%
Cameroon, 9, 0.07%
Trinidad and Tobago, 9, 0.07%
Malawi, 8, 0.06%
Barbados, 7, 0.05%
Pakistan, 7, 0.05%
Estonia, 5, 0.04%
Gambia, 5, 0.04%
Guatemala, 5, 0.04%
Honduras, 5, 0.04%
Indonesia, 5, 0.04%
Iraq, 5, 0.04%
Latvia, 5, 0.04%
Mozambique, 5, 0.04%
Rwanda, 5, 0.04%
Senegal, 5, 0.04%
Slovenia, 5, 0.04%
Bulgaria, 4, 0.03%
Botswana, 4, 0.03%
Dominica, 4, 0.03%
Côte d'Ivoire, 4, 0.03%
Lithuania, 4, 0.03%
Croatia, 4, 0.03%
Grenada, 3, 0.02%
Zimbabwe, 3, 0.02%
Cuba, 3, 0.02%
Cayman Islands, 3, 0.02%
Serbia, 3, 0.02%
Belarus, 2, 0.02%
Belize, 2, 0.02%
Haiti, 2, 0.02%
Guinea, 2, 0.02%
Zambia, 2, 0.02%
Qatar, 2, 0.02%
Mauritius, 2, 0.02%
Myanmar, 2, 0.02%
Namibia, 2, 0.02%
Nepal, 2, 0.02%
UAE, 2, 0.02%
Palestine, 2, 0.02%
Show all (70 more)
1000
2000
3000
4000
5000
6000
7000
8000
9000
10000

Publishing countries in 5 years

500
1000
1500
2000
2500
3000
3500
USA, 3351, 71.1%
United Kingdom, 225, 4.77%
Canada, 166, 3.52%
Australia, 112, 2.38%
China, 107, 2.27%
Germany, 102, 2.16%
Sweden, 101, 2.14%
France, 96, 2.04%
Netherlands, 88, 1.87%
Republic of Korea, 80, 1.7%
Nigeria, 75, 1.59%
Spain, 68, 1.44%
Puerto Rico, 67, 1.42%
Italy, 64, 1.36%
Denmark, 55, 1.17%
Japan, 49, 1.04%
Norway, 48, 1.02%
Brazil, 37, 0.79%
Mexico, 34, 0.72%
Colombia, 31, 0.66%
Saudi Arabia, 28, 0.59%
Turkey, 27, 0.57%
Greece, 22, 0.47%
Austria, 20, 0.42%
Israel, 18, 0.38%
Kenya, 18, 0.38%
Tanzania, 18, 0.38%
India, 17, 0.36%
Belgium, 16, 0.34%
Ethiopia, 16, 0.34%
Ghana, 15, 0.32%
Egypt, 15, 0.32%
New Zealand, 15, 0.32%
Poland, 14, 0.3%
Czech Republic, 14, 0.3%
Finland, 13, 0.28%
Switzerland, 13, 0.28%
Guam, 12, 0.25%
Ireland, 12, 0.25%
Malaysia, 11, 0.23%
Singapore, 11, 0.23%
Argentina, 10, 0.21%
Jamaica, 10, 0.21%
Vietnam, 9, 0.19%
Peru, 9, 0.19%
South Africa, 9, 0.19%
Portugal, 8, 0.17%
Iceland, 8, 0.17%
Lebanon, 8, 0.17%
Malawi, 8, 0.17%
Uganda, 7, 0.15%
Russia, 6, 0.13%
Georgia, 6, 0.13%
Cameroon, 6, 0.13%
Chile, 6, 0.13%
Indonesia, 5, 0.11%
Iran, 5, 0.11%
Mozambique, 5, 0.11%
Rwanda, 5, 0.11%
Trinidad and Tobago, 5, 0.11%
Botswana, 4, 0.08%
Hungary, 4, 0.08%
Costa Rica, 4, 0.08%
Pakistan, 4, 0.08%
Bahamas, 3, 0.06%
Barbados, 3, 0.06%
Honduras, 3, 0.06%
Grenada, 3, 0.06%
Dominica, 3, 0.06%
Zimbabwe, 3, 0.06%
Romania, 3, 0.06%
Thailand, 3, 0.06%
Belize, 2, 0.04%
Guatemala, 2, 0.04%
Qatar, 2, 0.04%
Côte d'Ivoire, 2, 0.04%
Latvia, 2, 0.04%
Myanmar, 2, 0.04%
Cayman Islands, 2, 0.04%
Palestine, 2, 0.04%
Saint Lucia, 2, 0.04%
Slovakia, 2, 0.04%
Estonia, 1, 0.02%
Bangladesh, 1, 0.02%
Benin, 1, 0.02%
Bulgaria, 1, 0.02%
Burundi, 1, 0.02%
Virgin Islands, U.S., 1, 0.02%
Haiti, 1, 0.02%
Gambia, 1, 0.02%
Zambia, 1, 0.02%
Yemen, 1, 0.02%
Cyprus, 1, 0.02%
Libya, 1, 0.02%
Lithuania, 1, 0.02%
Mauritius, 1, 0.02%
Mali, 1, 0.02%
Morocco, 1, 0.02%
Nepal, 1, 0.02%
Nicaragua, 1, 0.02%
Show all (70 more)
500
1000
1500
2000
2500
3000
3500